{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:21Z","timestamp":1790352561215,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jphs.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T23:25:05Z","timestamp":1724714705000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets"],"prefix":"10.1016","volume":"156","author":[{"given":"Fumitaka","family":"Kinugasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fushiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Akuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jphs.2024.08.005_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 6","key":"10.1016\/j.jphs.2024.08.005_bib2","doi-asserted-by":"crossref","first-page":"vi57","DOI":"10.1093\/annonc\/mdt344","article-title":"Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Waddell","year":"2013","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.jphs.2024.08.005_bib3","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jso.23940","article-title":"Differences in gastric cancer survival between the U.S. and China","volume":"112","author":"Strong","year":"2015","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib5","first-page":"26","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Przegl\u0105d Gastroenterol"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-016-0147-6","article-title":"Gastric cancer: current and evolving treatment landscape","volume":"35","author":"Sun","year":"2016","journal-title":"Chin J Cancer"},{"issue":"10","key":"10.1016\/j.jphs.2024.08.005_bib7","first-page":"3543","article-title":"The role of chemotherapy in metastatic gastric cancer","volume":"31","author":"Pasini","year":"2011","journal-title":"Anticancer Res"},{"issue":"21","key":"10.1016\/j.jphs.2024.08.005_bib8","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.jphs.2024.08.005_bib9","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of claudin18.2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.jphs.2024.08.005_bib10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jphs.2024.08.005_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-014-1705-4","article-title":"An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens","volume":"466","author":"Keira","year":"2015","journal-title":"Virchows Arch"},{"issue":"9","key":"10.1016\/j.jphs.2024.08.005_bib12","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/ijc.28857","article-title":"Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer","volume":"135","author":"Micke","year":"2014","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.jphs.2024.08.005_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1369\/0022155411420569","article-title":"Claudin-18 is an early-stage marker of pancreatic carcinogenesis","volume":"59","author":"Tanaka","year":"2011","journal-title":"J Histochem Cytochem"},{"issue":"12","key":"10.1016\/j.jphs.2024.08.005_bib14","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","article-title":"Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas","volume":"22","author":"Arnold","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jphs.2024.08.005_bib15","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdx367.012","article-title":"Preclinical characterization of IMAB362 for the treatment of gastric carcinoma","volume":"28","author":"Mitnacht-Kraus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jphs.2024.08.005_bib16","doi-asserted-by":"crossref","first-page":"S843","DOI":"10.1016\/j.annonc.2021.08.1370","article-title":"986P Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice","volume":"32","author":"Nishibata","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"OncoImmunology"},{"issue":"10389","key":"10.1016\/j.jphs.2024.08.005_bib18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jphs.2024.08.005_bib19","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2024.08.005_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.vascn.2016.07.006","article-title":"Comparison of three preclinical models for nausea and vomiting assessment","volume":"82","author":"Goineau","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"10.1016\/j.jphs.2024.08.005_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/fcp.12082","article-title":"Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron","volume":"28","author":"Goineau","year":"2014","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jphs.2024.08.005_bib22","series-title":"Biology and Diseases of the Ferret","first-page":"735","article-title":"The ferret in nausea and vomiting research: lessons in translation of basic science to the clinic","author":"Percie du Sert","year":"2014"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0028-3908(95)00137-9","article-title":"The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret","volume":"35","author":"Rudd","year":"1996","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.jphs.2024.08.005_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.1996.tb15761.x","article-title":"The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret","volume":"119","author":"Rudd","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2024.08.005_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1476-5381.1996.tb15388.x","article-title":"An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret","volume":"118","author":"Rudd","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.jphs.2024.08.005_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0028-3908(99)00172-0","article-title":"The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets","volume":"39","author":"Tattersall","year":"2000","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/ALN.0b013e31823c7e56","article-title":"Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain","volume":"116","author":"Torigoe","year":"2012","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.jphs.2024.08.005_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"W\u00f6ll","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jphs.2024.08.005_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","article-title":"Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals","volume":"481","author":"T\u00fcreci","year":"2011","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.jphs.2024.08.005_bib30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/0028-3908(87)90094-3","article-title":"Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs","volume":"26","author":"Costall","year":"1987","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jphs.2024.08.005_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00280-010-1339-4","article-title":"Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists","volume":"67","author":"Percie du Sert","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.jphs.2024.08.005_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.21608\/ejhbmt.2017.19690","article-title":"Chemotherapy-induced nausea and vomiting (CINV)","volume":"4","author":"Shazly","year":"2017","journal-title":"Egyptian Journal of Hematology and Bone Marrow Transplantation"},{"issue":"5","key":"10.1016\/j.jphs.2024.08.005_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00011-014-0712-x","article-title":"Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant","volume":"63","author":"Szitter","year":"2014","journal-title":"Inflamm Res"},{"issue":"11","key":"10.1016\/j.jphs.2024.08.005_bib34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/bph.13482","article-title":"5-HT3 receptors promote colonic inflammation via activation of substance P\/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis","volume":"173","author":"Utsumi","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"24","key":"10.1016\/j.jphs.2024.08.005_bib35","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jphs.2024.08.005_bib36","first-page":"24","article-title":"Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"Brafford","year":"2014","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.jphs.2024.08.005_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/ijmpo.ijmpo_151_19","article-title":"Olanzapine: the game-changer \u201cantiemetic\u201d","volume":"40","author":"Dhanushkodi","year":"2019","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861324000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861324000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T07:12:29Z","timestamp":1726902749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861324000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1347861324000616"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2024.08.005","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}